Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control

NCT00567996 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00567996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00567996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2007
Completion date
Not reported
Enrollment
1,002 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)